f65f4ed5-9726-4eff-8638-63752686d2c9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- ANGIOGENESIS+0.360
- UV_RESPONSE_DN+0.360
- MYOGENESIS+0.350
- TGF_BETA_SIGNALING+0.350
- APICAL_JUNCTION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- KRAS_SIGNALING_DN+0.240
- NOTCH_SIGNALING+0.210
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- OXIDATIVE_PHOSPHORYLATION-0.590
- E2F_TARGETS-0.580
- MYC_TARGETS_V1-0.580
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- G2M_CHECKPOINT-0.450
- MTORC1_SIGNALING-0.430
- DNA_REPAIR-0.400
- FATTY_ACID_METABOLISM-0.390
- PEROXISOME-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296795 | — | — | 0.947 |
| 2 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.939 |
| 3 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.922 |
| 4 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.915 |
| 5 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.907 |
| 6 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.906 |
| 7 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.903 |
| 8 | 4108a871-c064-4537-9331-e59798d7d492 | — | — | 0.902 |
| 9 | SRR9879291 | — | cohortMD2 | 0.900 |
| 10 | SRR15069598 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |